Patent classifications
C12Q1/6879
PROVENANCE TRACKING USING GENETIC MATERIAL
The present disclosure relates generally to systems and methods for association of information with a product using genetic material. In various embodiments, genetic material such as plasmids may be incorporated into and/or otherwise persistently associated with a product. The genetic material may be encoded with, among other things, information that may uniquely identify the product, provide details relating to the origins of the product, the handling, distribution, and/or chain of custody of the product, intellectual property rights and/or other rights associated with the product, and/or the like. By extracting and analyzing the genetic material from the product, information encoded in the genetic material may be obtained by an interested party.
PROVENANCE TRACKING USING GENETIC MATERIAL
The present disclosure relates generally to systems and methods for association of information with a product using genetic material. In various embodiments, genetic material such as plasmids may be incorporated into and/or otherwise persistently associated with a product. The genetic material may be encoded with, among other things, information that may uniquely identify the product, provide details relating to the origins of the product, the handling, distribution, and/or chain of custody of the product, intellectual property rights and/or other rights associated with the product, and/or the like. By extracting and analyzing the genetic material from the product, information encoded in the genetic material may be obtained by an interested party.
MEANS AND METHODS FOR ACCURATELY ASSESSING CLONAL IMMUNOGLOBULIN (IG)/T CELL RECEPTOR (TR) GENE REARRANGEMENTS
- Monika Ursula Helga Brüggemann ,
- Michaela Kotrová ,
- Henrik Knecht ,
- Nikolaos Darzentas ,
- Giovanni Cazzaniga ,
- Frédéric Bernard Louis Davi ,
- Jacobus Johannes Maria Van Dongen ,
- Ramón Garcia-Sanz ,
- David Gonzalez De Castro ,
- Patricia Johanna Theodore Groenen ,
- Michael Andreas Hummel ,
- Elizabeth Anne Macintyre-Davi ,
- Konstantinos Stamatopoulos ,
- Christiane Pott ,
- Jan Trka ,
- Anthonie Willem Langerak
The invention relates to means and methods for assessing clonal immunoglobulin (IG)/T cell receptor (TR) gene rearrangements in a clinical, diagnostic and/or research setting. Provided is a quality control composition comprising a mixture of genomic DNA isolated from a set of nine cultured cell lines, said set comprising the B cell lines ALL/MIK (ALL), Raji (Burkitt lymphoma), REH (B cell precursor ALL), TMM (CML-BC/EBV+B-LCL), TOM-1 (B cell precursor ALL), WSU-NHL (B cell lymphoma) and the T cell lines JB6 (ALCL), Karpas299 (ALCL) and MOLT-13 (ALL), or wherein one or more cell lines of said set is replaced with one or more other cell line(s) comprising the same IG/TR gene rearrangements. Also provided is a quality control composition consisting of essentially equimolar amounts of genomic DNA isolated from healthy human thymus, healthy human tonsil and healthy human peripheral blood mononuclear cells.
MEANS AND METHODS FOR ACCURATELY ASSESSING CLONAL IMMUNOGLOBULIN (IG)/T CELL RECEPTOR (TR) GENE REARRANGEMENTS
- Monika Ursula Helga Brüggemann ,
- Michaela Kotrová ,
- Henrik Knecht ,
- Nikolaos Darzentas ,
- Giovanni Cazzaniga ,
- Frédéric Bernard Louis Davi ,
- Jacobus Johannes Maria Van Dongen ,
- Ramón Garcia-Sanz ,
- David Gonzalez De Castro ,
- Patricia Johanna Theodore Groenen ,
- Michael Andreas Hummel ,
- Elizabeth Anne Macintyre-Davi ,
- Konstantinos Stamatopoulos ,
- Christiane Pott ,
- Jan Trka ,
- Anthonie Willem Langerak
The invention relates to means and methods for assessing clonal immunoglobulin (IG)/T cell receptor (TR) gene rearrangements in a clinical, diagnostic and/or research setting. Provided is a quality control composition comprising a mixture of genomic DNA isolated from a set of nine cultured cell lines, said set comprising the B cell lines ALL/MIK (ALL), Raji (Burkitt lymphoma), REH (B cell precursor ALL), TMM (CML-BC/EBV+B-LCL), TOM-1 (B cell precursor ALL), WSU-NHL (B cell lymphoma) and the T cell lines JB6 (ALCL), Karpas299 (ALCL) and MOLT-13 (ALL), or wherein one or more cell lines of said set is replaced with one or more other cell line(s) comprising the same IG/TR gene rearrangements. Also provided is a quality control composition consisting of essentially equimolar amounts of genomic DNA isolated from healthy human thymus, healthy human tonsil and healthy human peripheral blood mononuclear cells.
METHODS, COMPOSITIONS, AND DEVICES FOR THE RAPID DETERMINATION OF FETAL SEX
The present disclosure provides methods, compositions, and devices for the rapid and direct detection of the sex of a fetus. The disclosure also provides methods, compositions, and devices for detecting fetal nucleic acids in biological samples (e.g., blood, cervical mucus, or urine).
METHODS, COMPOSITIONS, AND DEVICES FOR THE RAPID DETERMINATION OF FETAL SEX
The present disclosure provides methods, compositions, and devices for the rapid and direct detection of the sex of a fetus. The disclosure also provides methods, compositions, and devices for detecting fetal nucleic acids in biological samples (e.g., blood, cervical mucus, or urine).
METHODS FOR GENDER DETERMINATION AND SELECTION OF AVIAN EMBRYOS IN UNHATCHED EGGS
The present invention, in some embodiments thereof, is directed to a method for selecting a gender of an avian fertilized unhatched egg obtained from the crossing of a transgenic male avian subject and a transgenic female avian subject. Further provided is a kit for preparing a transgenic avian subject.
METHODS FOR GENDER DETERMINATION AND SELECTION OF AVIAN EMBRYOS IN UNHATCHED EGGS
The present invention, in some embodiments thereof, is directed to a method for selecting a gender of an avian fertilized unhatched egg obtained from the crossing of a transgenic male avian subject and a transgenic female avian subject. Further provided is a kit for preparing a transgenic avian subject.
Diagnostic applications using nucleic acid fragments
Various embodiments are directed to applications (e.g., classification of biological samples) of the analysis of the count, the fragmentation patterns, and size of cell-free nucleic acids, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, such as viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).
Diagnostic applications using nucleic acid fragments
Various embodiments are directed to applications (e.g., classification of biological samples) of the analysis of the count, the fragmentation patterns, and size of cell-free nucleic acids, e.g., plasma DNA and serum DNA, including nucleic acids from pathogens, such as viruses. Embodiments of one application can determine if a subject has a particular condition. For example, a method of present disclosure can determine if a subject has cancer or a tumor, or other pathology. Embodiments of another application can be used to assess the stage of a condition, or the progression of a condition over time. For example, a method of the present disclosure may be used to determine a stage of cancer in a subject, or the progression of cancer in a subject over time (e.g., using samples obtained from a subject at different times).